Pharmacokinetics, pharmacodynamics, and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study. Science ShareTwitterFacebookXingLinkedin BAY 2433334clinical trialfactor XIapharmacodynamicspharmacokineticsphase 1safetytolerability You May Also Like Science 30. Januar 2023 Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects. Science 30. Januar 2023 Midazolam microdosing applied in early clinical development for drug-drug interaction assessment. Science 30. Januar 2023 The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive – A randomized controlled trial.
